3638 Background: Patients with locally advanced colon cancer (LACC) have a poor prognosis, and those with N+ or T4 staging are prone to developing metastases. Only about 5% pathological complete response rates were observed in neoadjuvant chemotherapy. We conducted a single-arm, phase II trial to evaluate the efficacy and safety of immunotherapy combined with chemotherapy in locally advanced colon cancer. Methods: LACC patients clinically staged as T4 or N2 with histologically confirmed microsatellite stable/mismatch repair proficient (MSS/pMMR) type untreated colon adenocarcinoma are eligible for enrollment. Participants received 2-6 cycles of neoadjuvant therapy consisting of capecitabine and oxaliplatin (CAPOX) plus tislelizumab, followed by complete mesocolic excision. The primary endpoint was the pathological complete response (pCR) rate. This study was registered at ClinicalTrials.gov (NCT06124378). Results: A total of 61 patients were enrolled with a median age of 54 years (IQR 43–62). 35 (57%) of the recruited patients had a cT4 tumor and 47 (77%) of the patients had N2. All patients received neoadjuvant CAPOX plus tislelizumab, while three patients were excluded from activity analyses due to adverse events and the patient decision. Among the remaining 58 patients, 16 (28%) patients received 2 cycles, 39 (67%) patients completed 4 cycles, and 3 patients (5%) received 6 cycles prior to surgery. 14% patients achieved clinical complete response and the overall response rate was 91% based on clinical efficacy, with no cases of progressive disease observed. The regimen achieved a pathological complete response (pCR) rate of 41.4%, with all patients undergoing R0 resection. The major pathological response rate was 51.7% (95% CI 38.6 to 64.6). In subgroup analyses, patients with right-sided tumors exhibited higher pCR rates (16 [47%, 95% CI 30–65] of 34, compared to 8 [33%, 95% CI 17–54] of 24 for left-sided cases. However, no statistically significant differences were observed between the subgroups. Treatment-related adverse events of any grade occurred in 52 (85.2%) of 61 patients. The most common adverse events were peripheral sensory neurotoxicity (37 [61%] of 61) and decreased appetite (31 [51%]). Grade 3 drug-related serious adverse events occurred in 8 (13%) patients while no grade 4–5 adverse events occurred. Conclusions: This prospective trial demonstrates that neoadjuvant tislelizumab plus CAPOX provides a promising treatment strategy with encouraging antitumor activity and a manageable safety profile for MSS/pMMR locally advanced colon cancer. Clinical trial information: NCT06124378 .

To investigate immune checkpoint inhibitors (ICIs) induced pancreatic injury (ICIPI), the prognostic effect of COVID-19 vaccine on cancer patients, and whether COVID-19 vaccine increases the incidence of ICIPI. We conducted a retrospective study of 256 stage IV cancer patients treated with ICIs at The First Affiliated Hospital of Anhui Medical University from January 2020 to November 2022. Data collected included pancreatic enzyme levels, treatment outcomes, and vaccination status. Statistical significance was determined using the χ2 test and Kaplan-Meier method (p < .05). Compared to the control group, the vaccinated group (p < .0001) and the group with elevated pancreatic enzyme levels (p = .044) demonstrated higher disease control rates, indicating a direct benefit of vaccination and enzyme monitoring on treatment outcomes. Additionally, vaccinated patients demonstrated longer overall survival versus unvaccinated patients (23.9 months [95% CI, 22.3–25.5] vs 23.6 months [95% CI, 21.1–26.2], HR = 0.45 [95% CI, 0.24–0.86], p = .015) and progression-free survival (17.2 months [95% CI, 14.3–20.1] vs 13.7 months [95% CI, 11.3–16.1], HR = 0.54 [95% CI, 0.36–0.82], p = .004). Importantly, the analysis revealed no significant association between vaccination and pancreatic injury (p = .46). Monitoring pancreatic enzymes can effectively evaluate the therapeutic impact in patients using ICIs. Patients vaccinated against COVID-19 experience better immunotherapy outcomes without an increased risk of ICIPI.

OBJECTIVE:To analyze patient satisfaction with letter-based communication of lung cancer screening (LCS) pulmonary nodule results. STUDY DESIGN:Prospective randomized controlled trial of LCS between May and December 2019. METHODS:All participants came from a prospective randomized controlled study on pulmonary nodule results in LCS with low-dose CT (LDCT) to analyze patient satisfaction, perception of information received via letters, preferred methods of receiving results, and dissatisfaction-related characteristics. RESULTS:A total of 153 patients were detected to have pulmonary nodules among 600 recruited participants in the lung cancer high-risk group screened using LDCT. Most of the patients were satisfied with receiving pulmonary nodule results via letters (78.4%; n = 120) and agreed that the letters contained an appropriate amount of information (83.7%; n = 128). Univariate logistic regression analysis revealed that satisfaction was related to age (OR, 0.905; 95% CI, 0.832-0.985), education level (OR, 0.367; 95% CI, 0.041-3.250), no family history of cancer (OR, 0.100; 95% CI, 0.011-0.914), and the number of nodules (OR, 6.028; 95% CI, 1.641-22.141). Of the patients who reported dissatisfaction with letter-based communication (7.2%; n = 11), the most common reasons cited were that they contained insufficient patient education materials and that it was difficult to comprehend the medical terminology. The majority of participants (61.4%; n = 94) reported that they would prefer the letter-based communication. No correlation was identified between satisfaction and gender, smoking status, alcohol consumption, risk factors, nodule size, or nodule location. CONCLUSIONS:Patients were generally satisfied with receiving their LCS pulmonary nodule results via letters, reporting that the letters included adequate information about their diagnosis and follow-up steps. This may provide a basis for feasible result communication via letters for cancer screening programs in underdeveloped regions in China.

PurposeThis study aims to assess the prognostic value of inflammatory markers and clinical features in advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients receiving anti-programmed death 1 (PD-1) treatment.MethodsBased on receiver operating characteristic curve (ROC) analysis, Youden’s indexes were applied to determine the cut-off values for inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocye ratio (dNLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). Wilcoxon test was conducted to evaluate the changes in above inflammatory markers. Kaplan-Meier method was utilized to estimate progression-free survival (PFS) and overall survival (OS), and the Log-rank test was used to compare the different survival between groups. Univariate and multivariate Cox regression analyses were performed to assess the prognostic value of inflammatory markers and clinical features.Results162 advanced or metastatic ESCC patients receiving anti-PD-1 treatment were enrolled in this retrospective study. The cut-off values of NLR, dNLR, MLR, PLR, and SII were 4.748, 2.214, 0.309, 250.505, and 887.895, respectively. NLR, dNLR, PLR, and SII declined significantly among the partial response (PR) (P<0.001, P<0.001, P=0.036, P<0.001), objective response rate (ORR) (P<0.001, P<0.001, P=0.036, P<0.001), and disease control rate (DCR) (P<0.001, P<0.001, P=0.038, P<0.001) groups, respectively. Significant increases were found in NLR (P<0.001), dNLR (P<0.001), MLR (P=0.001), and SII (P=0.024) when anti-PD-1 treatment failed. Multivariate Cox regression analysis indicated that NLR (P<0.001, P=0.002), lymph node metastasis (P=0.013, P=0.001), Eastern Cooperative Oncology Group Performance Status (ECOG PS) (P=0.008, P=0.002), and treatment lines (P=0.037, P=0.048) were significant prognostic indicators of PFS and OS. Additionally, SII (P=0.016) was also significantly related to OS in ESCC patients. The risk score model showed that low risk patients prolonged PFS and OS than those with middle or high risk (P<0.001, P<0.001).ConclusionInflammatory markers can reflect short-term outcomes of anti-PD-1 treatment for ESCC patients. NLR, lymph node metastases, ECOG PS, and treatment lines are significant prognostic indicators for PFS and OS. And the risk score model constructed based on the above factors has favourable prognostic predictive value.

目的:探讨安罗替尼三线及以上治疗晚期非小细胞肺癌的疗效及安全性.方法:收集2018年10月至2020年4月安徽医科大学第一附属医院收治的接受安罗替尼三线及以上治疗的晚期非小细胞肺癌患者25例,通过回顾性分析其临床资料及随访,观察安罗替尼的近期疗效、生存情况、不良反应及预后因素.结果:安罗替尼治疗晚期非小细胞肺癌的客观缓解率(objective response rate,ORR)为12％(3/25),疾病控制率(disease control rate,DCR)为80％(20/25);25例患者的中位无进展生存期(median progression-free survival,mPFS)为4.00(95％CI:2.78～5.22)个月,中位总生存期(median overall survival,mOS)为6.50(95％CI:4.05～8.95)个月;其中腺癌患者的mOS明显长于鳞癌患者,单因素分析示:性别、年龄、病理、美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)评分、手术史、放疗史、吸烟史、表皮生长因子受体(epidermal growth factor receptor,EGFR)突变等均与OS无明显相关性(均P>0.05).结论:安罗替尼三线及以上治疗晚期非小细胞肺癌的耐受性及安全性较好,在一定程度上可以控制病情进展,延长患者的生存时间.

针对目前绝缘接头广泛应用于防止钢制管道电化学腐蚀的阴极保护系统并且绝缘接头经常出现事故的情况,对绝缘接头产品、制造和检验流程、各工序质量控制要点、常见质量问题等方面进行了介绍,提出了绝缘接头质量控制要点及方法.结果表明:该方法应用于某工厂质量控制、气密性试验泄漏等实例,证明此方法对绝缘接头质量控制有效.

Background The timely addition of anlotinib to the nab-paclitaxel/gemcitabine regimen may further increase the treatment efficacy for pancreatic adenocarcinoma (PDAC), which has not yet been reported. Therefore, we aimed to compare the efficacy and safety of anlotinib plus nab-paclitaxel/gemcitabine in the first-line treatment of patients with unresectable or metastatic PDAC. Methods This was a retrospective cohort of patients with unresectable or metastatic PDAC performed in The First Affiliated Hospital of Anhui Medical University from August 17, 2019 to April 3, 2021. Patients who received anlotinib plus nab-paclitaxel/gemcitabine treatment were defined as the anlotinib plus chemotherapy group and patients who received nab-paclitaxel/gemcitabine were defined as the chemotherapy group. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes were the objective response rate (ORR), the disease control rate (DCR), and toxic side effects. Clinical data and follow-up information were mainly obtained from hospital records or by telephone. Results A total of 33 patients were included in this study, with 17 cases in the anlotinib plus chemotherapy group and 16 cases in the chemotherapy group. The median PFS (mPFS) of the anlotinib plus chemotherapy group was 5 months while the mPFS of the chemotherapy group was 2.7 months (P=0.0220). The median OS (mOS) of the anlotinib plus chemotherapy group was 9 months while the mOS of the chemotherapy group was 6 months (P=0.0060). The 3-month and 6-month PFS, and the 6- and 12-month OS of the anlotinib plus chemotherapy group were significantly higher than those of the chemotherapy group (P<0.05). The proportion of patients with hematological toxicities in the anlotinib plus chemotherapy group was not significantly higher than that in the chemotherapy group. Conclusions Anlotinib plus nab-paclitaxel/gemcitabine as a first-line treatment regimen is safe and may prolong survival compared with nab-paclitaxel/gemcitabine chemotherapy in patients with unresectable or metastatic PDAC. Randomized controlled trials with large sample sizes are warranted to further evaluate the treatment effects of anlotinib in PDAC. Keywords Pancreatic adenocarcinoma (PDAC); anlotinib; nab-paclitaxel/gemcitabine; progression-free survival (PFS); overall survival (OS)

Background:Sintilimab is a recombinant fully human anti-programmed death 1 (PD-1) monoclonal antibody that blocks the interaction of PD-1 with its ligand. We evaluated the safety and efficacy of sintilimab combined with chemotherapy and targeted therapy in the treatment of advanced malignant tumors.Methods:We performed a retrospective analysis of the clinical data of patients with advanced malignant tumors treated with sintilimab combined with chemotherapy and targeted therapy admitted to the Third Ward of the Department of Medical Oncology, First Affiliated Hospital of Anhui Medical University, China, from July 2019 to February 2021. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and related adverse reactions were analyzed.Results:A total of 48 patients with advanced malignant tumors treated with sintilimab combined with chemotherapy and targeted therapy. All 48 patients completed 2 courses of treatment, and the ORR and DCR were 20.83% and 81.25%. The median PFS for all patients in this study was 7 months, and the median OS was not yet reached. The median PFS for the first-line and second-line patients was 10 months, and the median OS was not yet reached. The median PFS for third-line and beyond patients was 7 months, and the median OS was 10 months. The differences in PFS and OS were both statistically significant. Adverse events occurred in 24 patients, of which 18 patients had grade I-II adverse events and 6 patients had grade III-IV adverse events.Conclusions:Sintilimab is an inexpensive PD-1 drug produced in China. Sintilimab combination therapy showed good safety in the treatment of advanced malignant tumors, with increases in the treatment efficacy and DCR for advanced tumors. Because of few adverse reactions and proven efficacy, sintilimab combination therapy can be used as an option for the treatment of advanced malignant tumors.

Background: The role of camrelizumab combined with chemotherapy as the second-line therapy in nonsquamous nonsmall cell lung cancer (NSCLC) remains unverified. The retrospective study investigated efficacy and safety of camrelizumab combined with chemotherapy in the treatment of nonsquamous NSCLC as the second-line therapy. Subjects and Methods: Patients of nonsquamous NSCLC who were already discharged or died of the First Affiliated Hospital of Anhui Medical University between August 2019 and September 2020. According to the treatment method, the patients who received chemotherapy were denoted as the C group and those who received camrelizumab plus chemotherapy were denoted as the C&C group. Statistical Analysis Used: Patients responses were statistically analyzed. The Cox proportional hazards regression model was used in the assessment of the prognostic value of factors. Furthermore, adverse event evaluation was estimated. Results: Of the 60 patients with nonsquamous NSCLC included in the research, 29 patients received chemotherapy, and 31 patients received camrelizumab plus chemotherapy. The objective response rate was 13.79% and 32.26% for chemotherapy and camrelizumab plus chemotherapy groups, and the disease control rate was 72.41% and 80.65%. The median progression-free survival (mPFS) in camrelizumab plus chemotherapy group was obviously higher than that in the chemotherapy group (9.67 vs. 6.87 months, P = 0.01). The median overall survival of the camrelizumab plus chemotherapy was longer than the chemotherapy (10.89 vs. 7.95 months, P < 0.01). In the current treatment, radiotherapy and smoking were independent risk factors for the mPFS of patients with nonsquamous NSCLC. The occurrence of adverse events was similar between chemotherapy and camrelizumab plus chemotherapy groups. Conclusions: Camrelizumab combined with chemotherapy was an effective regimen with manageable toxicity in treating nonsquamous NSCLC as the second-line therapy.

Objective: Since the nosocomial fungal infections increasingly emerge, we extensively investigated the fungal species stratification and antifungal sensitivity profiles, clinical characteristics and associated risk factors of immunosuppressed patients with clinically diagnosed invasive fungal infections (IFIs) in a tertiary hospital of Anhui province.Methods: In total, 112 subjects with immunosuppressive state were enrolled from a comprehensive tertiary hospital in Central China between July 2019 and December 2021.Eight-one fungal isolates were clinically recovered by fungus-culturing approaches.The identifications were conducted through a mass spectrometry detecting platform.The susceptibilities to antifungals were tested using the broth micro-dilution method, and the possible antifungal azole-resistance mechanism in specific Candida species was availably explored by sequencing.Patient medical profiles were accessed via the digitized retrieval system of hospital, from which clinical outcomes and multiple risk factors for immunosuppressed patients with clinically diagnosed IFIs were explicitly documented for evaluation.Results: Candida species predominated in clinically diagnosed IFIs of immunosuppressed patients (accounting for 88.88%), followed by Trichosporon and Aspergillus species (6.17% and 4.94%, respectively).The source types of specimen were primarily comprised of urine (41.98%), respiratory samples (33.33%) and peripheral blood (9.88%).Frequently isolated Candida and Trichosporon species exhibited a high level of in vitro sensitivity for amphotericin B and 5-fluorocytosine, whereas a substantial portion of Candida species including C. glabrata, C. parapsilosis complex and C. tropicalis, and Trichosporon species showed lowered sensitivity patterns toward itraconazole, fluconazole and voriconazole at different levels.Specifically, gene mutations of ERG11 were identified in azole-resistant C. tropicalis.Distinct risk factors were analyzed to be highly associated with the clinically diagnosed IFI incidence, mainly including hospitalization duration, surgical procedures, immunosuppressive treatments, underlying diseases and other conditions.Conclusion: Candida, Trichosporon and Aspergillus species were the top three pathogenic fungal agents causing clinically diagnosed IFIs in immunosuppressed patients.The attenuated sensitivity to azoles in Candida and Trichosporon species needs close surveillance, and ERG11 polymorphism might contribute to azole resistance in specific Candida species.Multiple featured risk factors for immunosuppressed patients developing clinically diagnosed IFIs require further consideration during clinical practice.

Background: Pancreatic cancer (PC) is one of the most lethal types of cancer with extremely poor diagnosis and prognosis, and the tumor microenvironment plays a pivotal role during PC progression. Poor prognosis is closely associated with the unsatisfactory results of currently available treatments, which are largely due to the unique pancreatic tumor microenvironment (TME). Methods: In this study, a total of 177 patients with PC from The Cancer Genome Atlas (TCGA) cohort and 65 patients with PC from the GSE62452 cohort in Gene Expression Omnibus (GEO) were included. Based on the proportions of 22 types of infiltrated immune cell subpopulations calculated by cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT), the TME was classified by K-means clustering and differentially expressed genes (DEGs) were determined. A combination of the elbow method and the gap statistic was used to explore the likely number of distinct clusters in the data. The ConsensusClusterPlus package was utilized to identify radiomics clusters, and the samples were divided into two subtypes. Result: Survival analysis showed that the patients with TMEscore-high phenotype had better prognosis. In addition, the TMEscore-high had better inhibitory effect on the immune checkpoint. A total of 10 miRNAs, 311 DEGs, and 68 methylation sites related to survival were obtained, which could be biomarkers to evaluate the prognosis of patients with pancreatic cancer. Conclusions: Therefore, a comprehensive description of TME characteristics of pancreatic cancer can help explain the response of pancreatic cancer to immunotherapy and provide a new strategy for cancer treatment.

目的：探讨腔镜甲状腺手术中喉返神经的解剖特点。方法2010年7月～2013年6月，经胸入路腔镜甲状腺手术64例，术中解剖颈段喉返神经42条（右侧31条，左侧11条），观察并记录与喉返神经相关的解剖标志和特点。结果除1例因甲状腺乳头状癌（肿块直径2．5 cm）突破包膜中转开放手术外，余63例均获成功。腔镜下用超声刀在甲状腺真假被膜之间进行分离，在甲状腺下动脉深面发现下甲状旁腺（40／42，95％），在下甲状旁腺深面可发现喉返神经（37／42，88％），下甲状旁腺可作为寻找喉返神经的解剖标志；喉返神经在甲状软骨后下角恒定入喉（42／42，100％），在喉返神经入喉前走行较浅（似有出沟抬头入喉之势）紧贴着甲状腺，其上有一条与该神经垂直的血管（V1）位于其表面（42／42，100％），在气管食管沟疏松结缔组织内有时会发现一条与喉返神经走行平行的血管（V2）（25／42，60％），该血管深面可发现喉返神经，V1和V2可作为寻找喉返神经的标志。结论喉返神经内镜下解剖应注重颈部解剖层次，遵循其与甲状腺下动脉、上下甲状旁腺、甲状腺中静脉、无名血管（ V1、V2）及环甲关节处等毗邻的关系，由浅入深、由简单到复杂、由一般到特殊进行解剖。

Objective To explore the feasibility and safety of laparoscopic directly hiatal hernia repair.Methods Retrospective analysis the clinical data of 38 patients under laparoscopic hiatal hernia repair from December 2012 to March 2015.Results 38 cases of laparoscopic hiatal hernia repair all success directly.5 routine stomach bottom part 270°fold surgery ( Toupet) 33 stomach bottom part 360°fold after operation( Nissen) operation time on average 50 to 150 minutes, the average operation time, 100 in laparoscopic hiatal hernia repair,15 to 60 ml blood loss,postoperative 24 hours to pull out the tube and liquid diet,no postoperative complications.Average hospital 7 days.Conclusion After the three months follow-up, 38 cases of patients with no recurrence of 35 cases with acid reflux,chest pain obviously improved compared with preoperative, for hiatal hernia, laparoscopic hiatal hernia repair surgery is a safe, reliable, effective treatment.

Objective To describe the quality of life(QOL) among the rural family heads in Dabie Mountain area and to determine its influential factors for making scientific policies and reasonable distribution of health resource. Methods Totally 3 920 family heads were randomly chosen with cluster sampling method from a town in Dabie Mountain area and were interviewed with a self-designed questionnaire. Results The total number of eligible questionnaire was 3 556(with a response rate of 90.7%,3 361 from the male and 195 from the female).The mean age of the family heads was 46.77±10.92 years.The mean score of QOL was 18.34±2.17 for the subjects.The univariate analyses showed that age,occupation,education level,marital status,economic condition,health status,and medical security had significant relation with OQL.The results of multiple linear regression found that subjective health satisfaction,health status,smoking,washing hands with soap or not,hospitalization in the latest year,seeing a doctor timely,sleep quality,disease history in latest two weeks,occupation,and age affected QOL among the rural family heads with statistical significances. Conclusion The QOL among the rural family heads in Dabie Mountain area is normal.Age,occupation,education level,health status are the significant predictors of quality of life.

Objective To examine the status of activities of daily living(ADL) and its influencing factors among rural elderly population in the Dabieshan Mountain area.Methods Totally 1 117 rural elderly aged 60 years and older were chosen with cluster sampling from a town of Dabieshan Mountain area and then their ADL was measured with a self-designed questionnaire and the influencing factors of ADL were analyzed with multinomial logistic regression.Results The total number of valid questionnaires was 1 117(353 for male and 764 for female).The mean age of the elderly was 70.17±6.624 years and the mean score of ADL was 19.37±7.097.The prevalence rate of reduced ADL in the elderly was 73.1%.The results of univariate analyses showed that age,marital status,chronic disease,and living condition could influence ADL in the eledrly(P<0.05).The results of logistic regression analysis revealed that age,economic control,whether with chronic disease,physical training,and living condition affected ADL of the elderly(P<0.05 for all).Conclusion The reduced ADL among rural elderly in Dabieshan Mountain area was prevalent and living condition and quality of life of the elderly should be improved.Age,physical training,economic control,whether with chronic disease,and living condition were significant predicting variables of ADL.

Objective To study status of condom use among HIV infectors and discuss associated factors.Methods A total of 197 HIV infectors and their family members,as well as local medical workers were selected from a project county of north part of Anhui province by using cluster sampling.Questionnaire survey was conducted by face-to-face interview.Result Among the 197 valid respondents,165 were HIV-infected people and 84.2%(139/165) of them were former blood donors.Most of the HIV infectors had a decline in their sex behaviors(53.3%)or even stopped their sex behaviors(18.3%);111(68.9%)persons consistently used condoms in their sexual intercourse,133(82.6%)persons used condoms in the latest sexual intercourse.Most of the respondents were supportive of using condoms,but few of them used condoms on their own initiative.Some of them had no idea how to use condoms correctly.They always got condoms from the township hospitals and thought that the condoms were in good quality.Conclusion The interviewed HIV infectors do not use condom correctly and persistently.It is necessary to take relevant and various interventions to improve condom use among this specific population group.

【Objective】 To understand the status of refractive errors in pre-school children so as to provide scientific basis for making reasonable intervention strategy.【Methods】 A total of 2 032 children aged 6 month~6 years old from daily outpatient clinics and nursery schools in Maanshan city were chosen by cluster sampling.Then their refractive statuses were measured suresight hand-hold refractomter,meanwhile handed out self-administrated questionnaire to the parents to investigated their knowledge and actions about protecting their children's visions.【Results】 In pre-school children the rate of refractive errors was 31.1%.The mainly type of refractive errors was astigmatism.With the increase of the age,the rate of refractive errors decreased in 6 months~6 years old children.The rate of refractive errors in live scattered children was significantly higher than those in nursery and kindergarten children.The rate in local children was significantly higher than those in nonlocal children.The understand rate of knowledge about vision protecting in parents was low,and the protecting action was lack.【Conclusion】 The rate of refractive errors is low among pre-school children in Maanshan city,health care department,education institution and parents should take more attention and strengthen cooperation to protect the children's visions.

Objective: To explore status and related factors of reproductive tract infections(RTIs) among rural married woman in Fuyang City in order to provide the scientific basis for further intervention.Methods: A stratified cluster sampling design was used and a questionnaire survey as well as clinical and laboratory examinations were conducted on 3 191 married women.Results: A total of 1 728(54.2%) women had at least one RTI,48.8% had at least two kinds of RTIs.The top five RTIs were acute and chronic cervicitis(32.3%),bacterial vaginosis(11.4%),vulvovaginal candidiasis(3.9%),trichomonal vaginitis(3.2%) and vuluitis(3.0%).The results of logistic regression showed that abortion,high parity and a tub bath were risk factors of RTIs.Conclusion: High prevalence rate of RTIs is found in rural married women of Fuyang City,which is related to multiple factors.Health education and routine gynecological examinations should be conducted to prevent RTIs.

Objective To explore current status of married women in regard to their use of contraceptive methods and to find out the correlation between contraceptive methods and induced abortion in order to provide evidence for reproductive healthcare in rural married women.Methods On the basis of keeping a representation of the cities,52 481 women aged 15-49 years were surveyed by using stratified-cluster-random sampling.Investigation and gynecological examination were conducted by two steps,firstly converging at the clinics,and then at homes of the women.Results In the previous 6 months,the total birth control rate of the women was 95.2%(n=49 970).The ratios of choosing permanent and nonpermanent contraceptive methods were 46.7%(n=24 481) and 48.5%(n=25 489),respectively.Female sterilisation was the first choice with a usage rate of 43.7%(n=22 916),followed by intrauterine device(IUD),which was used by 41.1%(n=21 563) of the women.Of the women choosing permanent contraceptive methods,25.2%(n=6 165) had a history of induced abortion.Among the women choosing nonpermanent contraceptive methods,38.0%(n=9 684) had a history of induced abortion.In the women never using contraceptive method during intercourse,37.9%(n=951) had a history of induced abortion.Single-variable analysis showed that the choice of contraceptive method was associated with induced abortion(χ2=983.16,P0.001).Conclusion The efficiency of contraception has a relation with induced abortion.The related department should carry out health education on contraception method in order to improve the efficiency of contraception and reduce the rate of induced abortion.

Objective:To understand the current situation and related factors of common reproductive tract infections(RTIs) among married women of childbearing age in rural area of Huainan city,in order to provide scientific basis for carrying out intervention project.Methods:3 193 married women of childbearing age were selected from Huainan city of Anhui province by stratified cluster sampling method,gynecological clinical examination and laboratory examination were carried out;the related knowledge,attitude and behavior of RTIs were investigated by a questionnaire.Results:Among 3 193 married women,2 246 women(70.3%) were diagnosed with RTIs,the first three diseases of RTIs were columnar ectopia(52.6%),cervical hypertrophy(33.0%) and bacterial vaginitis(11.0%).Multivariate logistic regression analysis showed that the rural married women with high average household annual income had low possibility of RTIs(OR=0.848,95%CI: 0.755~0.953),high income was a protective factor of RTIs;the rural married women with many times of reproduction(OR=1.263,95%CI: 1.081~1.476) and long interval of bathing in winter(OR=1.479,95%CI: 1.244~1.417) were apt to RTIs.Conclusion:The prevalence of RTI among married women in rural area of Huainan city is very high and affected by many factors.Health education and regular gynecological general investigation should be carried out to reduce the prevalence of RTI.